AAPS PharmSci 360
Event details
| Date: | November 3, 2019 - November 6, 2019 |
| Website: | |
| Location: | San Antonio, TX, United States, America |
AAPS PharmSci 360 combines all the energy of a large scientific conference with the intimacy of a niche meeting.
- Five robust tracks covering all aspects of the pharmaceutical sciences
- Dynamic Solution Center floor divided into neighborhoods that mirror the tracks
- Hundreds of exhibitors with dozens of additional learning opportunities
- Thousands of scientific posters featuring the latest, most innovative research in the field
- An indispensable Career Development Center offering management and communication training, as well as opportunities to update your LinkedIn profile and meet with recruiters
- Unlimited networking opportunities to build on existing relationships and grow new ones
Each track is split equally between chemical and biomolecule areas, resulting in 10 sub-tracks covering the research and challenges making the biggest headlines in the pharmaceutical sciences today.
Client information
Posters
A Drug-Drug Interaction Study: The Effect of Multiple Doses of Vatiquinone on the Single Dose Pharmacokinetics of Tolbutamide and Omeprazole (https://www.eventscribe.com/2019/PharmSci360/fsPopup.asp?efp=SUlFUEhHSFQ4MDkx&PosterID=240675&rnd=0.5406671&mode=posterinfo)
ChauHwei Fu, Peter Dogterom, Donald Burkindine, Thomas Chou, Christie Elliott, Martin Thoolen
Presentation Time: Tuesday, November 5 | 9:30 – 10:30 AM
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACT017, an Anti-platelet GPVI (Glycoprotein VI) Fab in Healthy Volunteers (https://www.eventscribe.com/2019/PharmSci360/fsPopup.asp?efp=SUlFUEhHSFQ4MDkx&PosterID=234611&rnd=0.605519&mode=posterinfo)
Peter Dogterom, Christine Voors-Pette, Thomas Chou, Laurien Jullien, Kristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard
Presentation Time: Tuesday, November 5 | 10:30 – 11:30 AM
Influence of Rifampin-Mediated OATP1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan (https://www.eventscribe.com/2019/PharmSci360/fsPopup.asp?efp=SUlFUEhHSFQ4MDkx&PosterID=234331&rnd=0.9433728&mode=posterinfo)
Peter Dogterom, Pierre-Eric Juif, Christine Voors-Pette, Mike Ufer, Jasper Dingemanse
Presentation Time: Tuesday, November 5 | 12:30 – 1:30 PM
A Drug-Drug Interaction Study: The Effects of Multiple Doses of the CYP3A4 Modulators Itraconazole and Rifampin on the Single Dose Pharmacokinetics of Vatiquinone (https://www.eventscribe.com/2019/PharmSci360/fsPopup.asp?efp=SUlFUEhHSFQ4MDkx&PosterID=234865&rnd=0.5200823&mode=posterinfo)
Peter Dogterom, ChauHwei Fu, Thomas Chou, Thomas Wade, Christie Elliott, Martin Thoolen
Presentation Time: Tuesday, November 5 | 2:30 – 3:30 PM
Making the right interpretation of biomarker data relies on the expertise of the scientist and the quality of the measurement methods. Well-established reagents are key to achieving assay robustness, specificity and sensitivity.
During the 2019 AAPS PharmSci 360, Hanna Ritzén, Managing Director R&D at Mercodia, will present Risk assessment, definition, characterization and control of critical reagents in biomarker assays in Classroom 5, Hall 234 on Tuesday (Nov 5th) at noon. Take the opportunity to learn more about critical reagents and the benefits of reagent characterization and control for your bioanalytical strategy.
Hanna Ritzén has worked with LBAs and critical reagents in a regulated setting for more than 15 years, and she will provide real-world examples of controlling reagents in problem-solving and managing lot-to-lot consistency strategies. How do we define critical reagents? Can we generalize? Why do we need to spend time on reagent characterization? How do we know that our control is enough? What do we do when we meet the unexpected?
After the presentation you are invited to our Partner Reception, giving you an opportunity to mingle with peers and discuss further with Hanna Ritzén and other Mercodia representatives.
See you in Classroom 5, Hall 234 on Nov 5th at noon!
Carissa Jones, President at Mercodia Inc
Poster information
- Development and Validation of an LC-MS.MS Method for the Simultaneous Quantitation of Fifteen Bile Acids in Human Serum
a. Authors:
i. Frontage: Kai Wang, Siliang Chen, Yafei Xu, Luca Matassa and Zhongping (John) Lin
ii. Mirum Pharmaceuticals: Pamela Vig
iii. Takeda (Shire at the time the work was performed): Hassan Rashidzadeh, Hongmei (Karen) Cao and Marita Larsson Cohen
2. Overcoming Stability Issues in the Development of an LC-MS.MS Method for the Quantitation of Azacitidine in Human Plasma
a. Authors: Junyi Yang, Bin Dai, Liqing Jin, Xiaonan Tang, Luca C Matassa and Zhongping (John) Lin
3. Quantitation of Myostatin.GDF-8 in Human Serum Using an Enzyme Linked Immunosorbent Assay (ELISA)
a. Authors: Xuesong Chen1, Wenqing Song1, Weiping Shao1, Zhongping (John) Lin1, Yizhang Chen, Mi Huang2 and Sudhakar Pai2
4. Simultaneous Determination of Coproporphyrin-I and Coproporphyrin-III in Human Plasms and Human Urine Using LC-MS.MS
a. Authors: Wei Zhang, Yong Yan, Jim Xiao, XiaoNan Tang, Luca C. Matassa, and ZhongPing (John) Lin.
Meet with Q2 Solutions at the AAPS PharmaSci 360, booth #1527, and learn how our dedicated project managers can deliver the science and logistics of your projects faster
San Antonio, Texas | November 03, 2019 – November 06, 2019 | 09:00 – 18:0
For for information, please click here
For more information including exhibitor information, the full agenda and registration details, click here.